BioSpace News Archive

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).

Virios Therapeutics, Inc. today announced plans for advancing IMC-2 (combination of valacyclovir and celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with LC, also known as post-acute sequelae of SARS-CoV-2 infection (“PASC”).

NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd, announced today that the European Commission (EC) has granted orphan drug designation to NS-229, which is being developed for the treatment of the rare disease eosinophilic granulomatosis with polyangiitis (EGPA).

SS Innovations International, Inc. is proud to have presented the inaugural SS Innovations Multi-Specialty Robotic Surgical Conference, that was held at The Leela Ambience Hotel in Gurugram, Haryana, India on January 19 and 20, 2024.

ALZpath, Inc. (ALZpath), a leader in Alzheimer’s diagnostics, announced new findings published online today in JAMA Neurology showing that its proprietary blood-based biomarker assay for phosphorylated tau at residue 217 (pTau217) delivers high diagnostic accuracy and consistency in identifying amyloid and tau in the brain.

BioUtah, Utah’s trade association dedicated to the life sciences community, in partnership with the University of Utah’s Technology Licensing Office, today announced a venue change and speaker update for the 2024 Entrepreneur and Investor Life Sciences (E&I Summit) sponsored by Wilson Sonsini.

ABANZA is excited and honored to announce the strategic addition of Executive Vice President for US operations, JOHN RIZZO.

Evaxion Biotech A/S announced that the Company’s previously disclosed change to its ratio of its American Depositary Shares to its ordinary shares, DKK 1 nominal value, has been made effective.

Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial, reducing the risk of death by 28% in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) vs. sunitinib after eight years, regardless of International Metastatic RCC Database Consortium (IMDC) risk group.

In another milestone since the implementation of CAR-T therapy at Jiahui, the first myeloma patient treated with CAR-T at Jiahui International Hospital was recently discharged two weeks after infusion.